newsfilter
← Latest News
GlobeNewswire·

RVL Pharmaceuticals plc Reports First Quarter 2022 Financial Results; Provides Commercial Update

First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 R